Clinical Scorecard: Reducing Injections in Wet AMD
At a Glance
| Category | Detail |
|---|---|
| Condition | Wet Age-related Macular Degeneration (AMD) |
| Key Mechanisms | Tyrosine kinase inhibitors targeting VEGF pathways |
| Target Population | Patients with wet AMD requiring frequent injections |
| Care Setting | Ophthalmology clinics and specialized retinal practices |
Key Highlights
- EYP-1901 is a potent anti-VEGF/pan-VEGF inhibitor designed for extended release.
- Patients in the DAVIO2 trial had an average of 10 injections in the year prior.
- Post-treatment, patients required only 1 to 2 supplemental injections annually.
Guideline-Based Recommendations
Diagnosis
- Assess visual acuity and retinal imaging for wet AMD diagnosis.
Management
- Consider EYP-1901 for patients with high treatment burden from anti-VEGF therapy.
Monitoring & Follow-up
- Regular follow-up for visual acuity and retinal health post-injection.
Risks
- Monitor for potential adverse effects related to tyrosine kinase inhibitors.
Patient & Prescribing Data
Patients with wet AMD experiencing high injection frequency.
EYP-1901 may significantly reduce the need for frequent injections.
Clinical Best Practices
- Evaluate patient history of injection frequency before initiating EYP-1901.
- Ensure informed consent regarding the new treatment modality.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
